Vaxart

San Francisco, United States Founded: 2004 • Age: 22 yrs Listed
Developer of therapeutic solutions for treating multiple infectious diseases

About Vaxart

Vaxart is a publicly listed company based in San Francisco (United States) founded in 2004. Developer of therapeutic solutions for treating multiple infectious diseases. Vaxart has raised $57.97 million across 11 funding rounds from investors including HHS, Care Capital Management and Care Capital. The company has 115 employees. Vaxart offers products and services including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is Vaxart Inc. Its competitors include Adaptive Biotechnologies, Moderna and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.

Company details

Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.

  • Headquarters San Francisco, United States
  • Employees 115
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website vaxart.com
  • Social LinkedIn
  • Legal Name Vaxart, Inc.
Key Metrics
  • Annual Revenue
    $237.26 M (USD)
    726.68
    as on Dec 31, 2025
  • Net Profit
    $16.33 M (USD)
    as on Dec 31, 2025
  • EBITDA
    $26.65 M (USD)
    as on Dec 31, 2025
  • Total Equity Funding
    $57.97M (USD)

    in 11 rounds

  • Latest Funding Round
    $18.4M (USD), Series C

    Jan 2015

  • Investors
    HHS

    & 5 more

  • Employee Count
    115

Products & Services of Vaxart

Vaxart offers a comprehensive portfolio of products and services, including Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.

Oral Pill Vaccines
Vaccine Products

Vaccines delivered as oral pills for immunity against viral diseases.

VAAST Platform
Technology Platform

Platform for developing oral recombinant vaccines.

Mucosal Immunity Platform
Technology Platform

Platform focused on enhancing mucosal immune responses.

Funding Insights of Vaxart

Vaxart has successfully raised a total of $57.97M across 11 strategic funding rounds. The most recent funding activity was a Series C round of $18.4 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $57.97M
  • Total Rounds 11
  • Last Round Series C β€” $18.4M
  • First Round $2.78M

    (Apr 2007)

  • Investors Count 6

Latest 10 of 11 funding rounds of Vaxart with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2015$18.4MSeries C–Care Capital Management
–
Aug 2013$20MSeries C––
–
Jun 2012$16.87MSeries B–Care Capital, Quantum Technology Partners
–
Sep 2009$1.25MGrant––
Aug 2009$2.78MGrant––
Jul 2009$340,505Grant––
Aug 2008$340,505Grant––
Jul 2008$340,505Grant––
Nov 2007$2.7MSeries A–Quantum Technology Partners, Life Science Angels
–
Nov 2007$600,000Grant––
Valuation history

6 investors in total: 6 institutional.

Investors in Vaxart

Vaxart has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Care Capital Management and Care Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
carecapital.com
quantumtp.com
Life sciences startups are funded by a non-profit angel network.
lifescienceangels.comSunnyvale, United States
sbir.nih.gov
carecapitalmanagement.com
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Vaxart

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Vaxart

60 people are tracked at Vaxart (20 in leadership, 18 in board & advisors, 22 in team); the tracked headcount is 115.

NameRoleGroup
Jon Lindbloom
Director Of Technical OperationsLeadership
Laurie Hastings
Vice President Human ResourcesLeadership
Becca Flitter
Director Of ImmunologyLeadership
James F. Cummings
Chief Medical OfficerLeadership
Malik Rafi
Vice President, ManufacturingLeadership
Dana Opas
Director, Clinical Program ManagementLeadership
Maria Apkarian
Vice President Clinical OperationsLeadership
Nicholas D’Amato
Director, Clinical OperationsLeadership
Gargi Choudhary
Vice President, Analytical DevelopmentLeadership
Steven Lo
CEOLeadership
Sean Tucker
SVP & Chief Scientific OfficerLeadership
Molly Braun
Associate Director, ImmunologyLeadership
James Lay
Vice President Information TechnologyLeadership
Raymond D. Stapleton
Chief Technology OfficerLeadership
Vu Tran
Director Of Drug ProductLeadership
William Sun
Senior DirectorLeadership
Emilia Bora
Director, Analytical DevelopmentLeadership
Jerlisa Ann Arizala
Associate DirectorLeadership
Pam de Moor
Vice President, FormulationsLeadership
Gina Mastrosimone
Vice President, Business Strategy And PlanningLeadership

40 more people are available in the full profile.

Premium access

Complete people profiles for Vaxart

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Vaxart

Vaxart is a publicly listed company on the OTC with ticker symbol VXRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date12 Feb 2018
  • Listed onNASDAQ: VXRT
  • Listed entityVaxart, Inc.
  • Exchange sectorHealth technology
  • ISINUS92243A2006
  • Share price$0.46 (+3.8% on the day) · 2026-10-13
  • Market capitalisation$110.9M
  • Price to earnings2.9
  • EPS (diluted, trailing year)$0.16
  • Volume (last session)329,050

Financials of Vaxart

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$237.3M$16.3M$26.6M
2024$28.7M-$67.0M-$61.9M
2023$7.4M-$82.5M-$78.8M
2022$107,000-$107.8M-$107.1M
2021$892,000-$70.5M-$67.3M
Premium access

Detailed financial statements for Vaxart

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Vaxart

4 dated milestones of Vaxart across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Vaxart is founded.
  2. Funding First funding round of $2.8M.
  3. Funding Latest funding round, Series C, of $18.4M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Vaxart

Vaxart has 3 listed competitors in our database, 3 of them funded. They include Adaptive Biotechnologies, Moderna and Generate Biomedicines.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
adaptivebiotech.com2009Seattle, United States$419.15M609
Clinical diagnostics and drug discovery for immune diseases are provided.
modernatx.com2010Cambridge, United States$2.78B1,312
mRNA-based therapeutics for diseases including cancer and infections are developed.
generatebiomedicines.com2018Somerville, United States$643M286
Developer of novel protein-based therapeutics using machine learning and biological engineering
Premium access

Detailed competitors of Vaxart

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Vaxart

The website of Vaxart (vaxart.com) receives about 4.8K visits a month and ranks #4,483,544 among all websites worldwide, #5,417 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4.8K

    ▲ 20.1% vs previous month

  • Unique visitors
    1.6K

    per month

  • Global rank
    #4,483,544

    among all websites

  • Category rank
    #5,417

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Vaxart. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
sanofipasteur.com
sanofipasteur.com
100%
–
fiercebiotech.com
95%
858.3K#81,022View details
contagionlive.com
contagionlive.com
74%
#501,198–
cheetah-medical.com
69%
View details
vaccineindia.org
vaccineindia.org
63%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 20 similar websites and full traffic analytics for Vaxart

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 20 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Immunology & Cancer Therapeutics

3 companies that operate in the same segment as Vaxart (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Targeted and immune-oncology drugs for cancer treatment are developed.
2010Cambridge, Massachusetts, United StatesUSD 172 M
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Vaxart

Premium access

Complete news archive for Vaxart

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vaxart

Vaxart was founded in 2004 and raised its 1st funding round 3 years after it was founded.

Vaxart is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

Vaxart is a funded company, having raised a total of $57.97M across 11 funding rounds to date. The company's 1st funding round was a Series A of $2.7M, raised on Apr 2007.

Vaxart has 115 employees.

Annual revenue of Vaxart is $237.26M as on Dec 31, 2025.

Founded in 2004 and based in San Francisco, United States, oral vaccines targeting infectious diseases are developed by Vaxart within the biotechnology sector. A proprietary delivery platform is employed to produce recombinant vaccines, with the pipeline covering seasonal influenza, norovirus, RSV, HSV-2, avian influenza, and Ebola. Vaccines addressing influenza treatment are also included in the offerings.

Vaxart's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

Vaxart offers Oral Pill Vaccines, VAAST Platform, and Mucosal Immunity Platform.

Yes, Vaxart is publicly traded on OTC under the ticker symbol VXRT.

Vaxart has 6 investors. Key investors include HHS, Care Capital Management, Care Capital, Quantum Technology Partners, and Life Science Angels.

Vaxart operates through Vaxart Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available